NCT00343239

Docetaxel in Locally Advanced Gastric Adenocarcinoma

Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Study objectives: To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.

Conditions

• Stomach Neoplasms

Interventions

Type	Name	Description
DRUG	Docetaxel	Formulation: infusion solution Route of administration: IV infusion on the first day of each 21-day cycle Dose regimen: 75 mg/m2
DRUG	Cisplatin	Formulation: infusion solution Route of administration: IV infusion on the first day of each 21-day cycle Dose regimen: 75 mg/m2
DRUG	Fluorouracil	Formulation: infusion solution Route of administration: IV infusion on the first day of each 21-day cycle Dose regimen: 750 mg/m2/day for 5 days

Timeline

• Start date: 2006-06-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2006-06-22
• Last updated: 2014-11-04

Locations

1 site across 1 country: Turkey (Türkiye)